Medicare Transplant Claims Surged 7,100% in Six Years. The Federal Government Is Now Charging 455 People.

From 2019 to 2025, Medicare claims for tissue and organ transplants — known as allografts — grew from $200 million to $14.4 billion. That's a 7,100% increase in six years, according to the Centers for Medicare and Medicaid Services.

CMS Administrator Mehmet Oz disclosed those figures at a press conference in Milwaukee. "That's a lot of money," Oz said. "And that bankrupts not just hospital systems and physician groups, but it causes major problems across the entire landscape."

The agency identified 4,200 suspicious allograft claims totaling $224 million in charges through May 2026. Since March, CMS has denied 96% of claims in that category.

How a number that large — $14.4 billion — built up over six years without triggering earlier enforcement is a question neither CMS nor the Justice Department has answered publicly.

What the Criminal Cases Actually Look Like

Federal prosecutors announced charges against 455 defendants tied to more than $6.5 billion in alleged fraud, according to the Washington Examiner. Ninety of those defendants are doctors or other licensed medical professionals.

Two cases stand out for scale. One involves a transnational criminal organization accused of submitting more than $3.7 billion in fraudulent Medicare claims for durable medical equipment that beneficiaries never requested and never received. A second alleges that healthcare executives billed Medicare more than $4 billion for wound care products while paying illegal kickbacks to keep the scheme running.

Prosecutors also announced what the Justice Department describes as the largest Medicaid fraud operation in its history: 295 defendants charged with submitting $518 million in false claims.

Beyond the dollar figures, prosecutors say some defendants exploited homeless people, individuals with addiction disorders, and elderly patients by using their identities to generate fake claims.

Durable Medical Equipment: Wheelchairs, Walkers, Hospital Beds

The allograft surge isn't the only front. CMS suspended payments to 102 durable medical equipment suppliers and revoked billing privileges for an additional 725 suppliers. Those suspended suppliers represented 8.6% of all Medicare-funded DME in 2025.

A spokesperson for Vice President JD Vance's office told Fox News Digital that the task force "effectively wiped out Durable Medical Equipment fraud in America" within six months, citing a moratorium on new DME companies combined with DOJ and HHS enforcement actions. That claim is the administration's own characterization. Independent auditors have not yet validated it.

In addition to the criminal cases, federal officials say the Department of Health and Human Services prevented more than $10 billion in fraudulent Medicare payments from going out the door, according to the Washington Examiner.

How Big Is the Underlying Problem

The Government Accountability Office estimated that the federal government made roughly $186 billion in improper payments last year. Medicare and Medicaid were responsible for more than half of that total.

Not all improper payments are fraud. Billing errors, documentation failures, and legitimate disputes make up a share. But the criminal prosecutions make clear that organized, large-scale theft from these programs is real and ongoing.

The Strongest Counterargument Deserves a Hearing

Critics of aggressive Medicare enforcement raise a legitimate concern: broad crackdowns can sweep up providers who made honest documentation errors alongside actual fraudsters. Denying 96% of allograft claims since March is a dramatic number. If a meaningful share of those denials hits legitimate providers — rural hospitals, community surgical centers, legitimate tissue banks — the collateral damage could affect real patients waiting on covered procedures.

CMS has not released a breakdown of how many of the 4,200 flagged claims were ultimately confirmed fraudulent versus erroneous versus legitimate. That number matters. Enforcement that's too blunt can strand patients and drive honest providers out of Medicare participation, which creates its own access problems. The administration should be transparent about its error rate as this crackdown scales.

What Happens Next

Federal officials say they are increasingly using data analytics and financial intelligence tools to catch suspicious billing patterns before payments go out, rather than recovering money after the fact. That shift from pay-and-chase to predictive denial is the structural change that will determine whether these enforcement numbers hold.

Sally C. Pipes, president of the Pacific Research Institute, wrote in the Washington Examiner that the urgency of these efforts "is hard to overstate" and called on the Trump administration to keep healthcare fraud as a central enforcement priority.

The unresolved question is whether CMS can sustain the 96% denial rate on allograft claims, or whether legal challenges from providers contesting those denials will force the agency to narrow its criteria. Several of the largest suspended DME suppliers have not yet been charged criminally, meaning billing suspension and criminal prosecution are still on separate tracks. How many of those 725 suppliers with revoked privileges end up facing indictments will be a concrete measure of how solid the underlying evidence is.